EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access

Lower Tuberculosis Incidence Among People With HIV Who Completed Isoniazid Preventive Therapy in Ukraine, a High-Burden Multidrug-Resistant Tuberculosis Setting: A Retrospective Cohort Study

Olutomi Sodeke iD, N Sarita Shah iD, Sherri Pals iD, Serhii Riabokon, Olena Samsonova, Fadimatu Mishara, Ivan Doan, Larysa Hetman, Ezra Barzilay, Nataliya Podolchak, Juliana Da Silva

Clinical Infectious Diseases · 2025

DOI: 10.1093/cid/ciaf069 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Clinical Infectious Diseases, 2025. Verfasst von Olutomi Sodeke und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Global HIV and Tuberculosis, Global Health Center, Centers for Disease Control and Prevention, Atlanta, Georgia, USA. Hauptthemen laut MEDLINE: Isoniazid, Tuberculosis, Multidrug-Resistant, Antitubercular Agents, HIV Infections. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Gates Foundation, PEPFAR, NIAID NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Evidence shows that isoniazid preventive therapy (IPT) reduces tuberculosis (TB) incidence among people with human immunodeficiency virus (HIV) with additive benefit beyond antiretroviral therapy alone, but its effectiveness in settings with high multidrug-resistant TB (MDR-TB) burden is unclear. We assessed the relationship between IPT and TB incidence among people with HIV (PWH) in Ukraine, a high-burden (32.6%) MDR-TB setting, and whether its effectiveness is maintained among virologically suppressed persons.

Methods

We analyzed national surveillance data for HIV and TB collected between 2018 and 2022. Complete IPT (n = 40 733) was defined as receipt of ≥146 days of therapy and no IPT (n = 91 022) as <28 days of therapy. We modeled TB incidence and death using Poisson regression adjusting for covariates related to receipt of IPT and TB incidence. The secondary outcome was multidrug resistance, and sensitivity analyses explored the influence of virologic suppression.

Results

Of 131 755 PWH who met inclusion criteria, 9089 (5.5%) died. Unadjusted TB incidence was 1.91 cases per 100 person-years in the No IPT group and 1.01 cases per 100 person-years in the Complete IPT group (adjusted incidence rate ratio [aIRR], 1.99). MDR-TB occurred in 29.1% and 30.7% of TB cases in the Complete and No IPT groups, respectively. Among virologically suppressed PWH, persons with no IPT had a higher TB incidence (aIRR, 1.38) than those who completed IPT.

Conclusions

Completing IPT as part of a public health intervention can significantly reduce TB incidence among PWH, even in settings with high-burden MDR-TB and among the virologically suppressed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

IsoniazidTuberculosis, Multidrug-ResistantAntitubercular AgentsHIV InfectionsTuberculosisHumansUkraineIncidenceMaleFemaleRetrospective StudiesAdultMiddle AgedYoung AdultAdolescent

Stichwörter der Autor:innen

HIVepidemiologymultidrug resistancetuberculosis

Substanzen

IsoniazidAntitubercular Agents

Autor:innen und Institutionen

  • Division of Global HIV and Tuberculosis, Global Health Center, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Epidemic Intelligence Service, Global Health Center, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, Georgia, USA.
  • Public Health Center of Ukraine, Ministry of Health, Kyiv, Kyiv Oblast, Ukraine.
  • Infectious Disease Program, National Foundation for the Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Division of Global HIV and Tuberculosis, Global Health Center, Centers for Disease Control and Prevention Ukraine, Kyiv, Kyiv Oblast, Ukraine.

ORCID-Profile: Olutomi Sodeke, N Sarita Shah, Sherri Pals

Förderung

  • Gates Foundation
  • PEPFAR
  • NIAID NIH HHS
  • Intramural CDC HHS
  • CDC Foundation

Zitieren

APA

Sodeke, O., Shah, N. S., Pals, S., Riabokon, S., Samsonova, O., Mishara, F., Doan, I., Hetman, L., Barzilay, E., Podolchak, N., & Da Silva, J. (2025). Lower Tuberculosis Incidence Among People With HIV Who Completed Isoniazid Preventive Therapy in Ukraine, a High-Burden Multidrug-Resistant Tuberculosis Setting: A Retrospective Cohort Study. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciaf069

Vancouver

Sodeke O, Shah NS, Pals S, Riabokon S, Samsonova O, Mishara F, et al. Lower Tuberculosis Incidence Among People With HIV Who Completed Isoniazid Preventive Therapy in Ukraine, a High-Burden Multidrug-Resistant Tuberculosis Setting: A Retrospective Cohort Study. Clinical Infectious Diseases. 2025. doi:10.1093/cid/ciaf069

BibTeX
@article{Sodeke2025,
  author = {Sodeke, Olutomi and Shah, N Sarita and Pals, Sherri and Riabokon, Serhii and Samsonova, Olena and Mishara, Fadimatu and Doan, Ivan and Hetman, Larysa and Barzilay, Ezra and Podolchak, Nataliya and Da Silva, Juliana},
  title = {Lower Tuberculosis Incidence Among People With HIV Who Completed Isoniazid Preventive Therapy in Ukraine, a High-Burden Multidrug-Resistant Tuberculosis Setting: A Retrospective Cohort Study},
  journal = {Clinical Infectious Diseases},
  year = {2025},
  doi = {10.1093/cid/ciaf069}
}
Kostenlos starten →